排序方式: 共有20条查询结果,搜索用时 78 毫秒
1.
Dan H. Barouch Kathryn E. Stephenson Erica N. Borducchi Kaitlin Smith Kelly Stanley Anna G. McNally Jinyan Liu Peter Abbink Lori F. Maxfield Michael S. Seaman Anne-Sophie Dugast Galit Alter Melissa Ferguson Wenjun Li Patricia L. Earl Bernard Moss Elena E. Giorgi James J. Szinger Leigh Anne Eller Erik A. Billings Mangala Rao Sodsai Tovanabutra Eric Sanders-Buell Mo Weijtens Maria G. Pau Hanneke Schuitemaker Merlin L. Robb Jerome H. Kim Bette T. Korber Nelson L. Michael 《Cell》2013
2.
Lawrence J. Tartaglia Hui-Wen Chang Benjamin C. Lee Peter Abbink David Ng’ang’a Michael Boyd Christy L. Lavine So-Yon Lim Srisowmya Sanisetty James B. Whitney Michael S. Seaman Morgane Rolland Sodsai Tovanabutra Jintanat Ananworanich Merlin L. Robb Jerome H. Kim Nelson L. Michael Dan H. Barouch 《PLoS pathogens》2016,12(2)
Simian-human immunodeficiency virus (SHIV) challenge stocks are critical for preclinical testing of vaccines, antibodies, and other interventions aimed to prevent HIV-1. A major unmet need for the field has been the lack of a SHIV challenge stock expressing circulating recombinant form 01_AE (CRF01_AE) env sequences. We therefore sought to develop mucosally transmissible SHIV challenge stocks containing HIV-1 CRF01_AE env derived from acutely HIV-1 infected individuals from Thailand. SHIV-AE6, SHIV-AE6RM, and SHIV-AE16 contained env sequences that were >99% identical to the original HIV-1 isolate and did not require in vivo passaging. These viruses exhibited CCR5 tropism and displayed a tier 2 neutralization phenotype. These challenge stocks efficiently infected rhesus monkeys by the intrarectal route, replicated to high levels during acute infection, and established chronic viremia in a subset of animals. SHIV-AE16 was titrated for use in single, high dose as well as repetitive, low dose intrarectal challenge studies. These SHIV challenge stocks should facilitate the preclinical evaluation of vaccines, monoclonal antibodies, and other interventions targeted at preventing HIV-1 CRF01_AE infection. 相似文献
3.
Gerhardt M Mloka D Tovanabutra S Sanders-Buell E Hoffmann O Maboko L Mmbando D Birx DL McCutchan FE Hoelscher M 《Journal of virology》2005,79(13):8249-8261
Co-infections with more than one human immunodeficiency virus type 1 (HIV-1) subtype appear to be the source of new recombinant strains and may be commonplace in high-risk cohorts exposed to multiple subtypes. Many potential dual infections have been identified during the HIV Superinfection Study in Mbeya, Tanzania, where 600 female bar workers who are highly exposed to subtypes A, C, and D have been evaluated every 3 months for over 3 years by use of the MHAacd HIV-1 genotyping assay. Here we describe an in-depth, longitudinal analysis of the viral quasispecies in a woman who was triply infected with HIV-1 and who developed AIDS and passed away 15 months after enrollment. The MHA results obtained at 0, 3, 6, 9, and 12 months revealed dual-probe reactivities and shifts in subtype over time, indicating a potential dual infection and prompting further investigation. The multiple infection was confirmed by PCR amplification of three genome regions by a multiple primer approach, followed by molecular cloning and sequencing. A highly complex viral quasispecies was found, including several recombinant forms, with vpu/gp120 being the most diverse region. A significant fluctuation in molecular forms over time was observed, showing that the serial sample format is highly desirable, if not essential, for the identification of multiple infections. In a separate experiment, we confirmed that the detection of co-infections is more efficient with the use of multiple amplification primers to overcome the primer bias that results from the enormous diversity in the HIV-1 genome. 相似文献
4.
In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection 下载免费PDF全文
McCutchan FE Hoelscher M Tovanabutra S Piyasirisilp S Sanders-Buell E Ramos G Jagodzinski L Polonis V Maboko L Mmbando D Hoffmann O Riedner G von Sonnenburg F Robb M Birx DL 《Journal of virology》2005,79(18):11693-11704
Human immunodeficiency virus type 1 (HIV-1) superinfection refers to the acquisition of another strain by an already infected individual. Here we report a comprehensive genetic analysis of an HIV-1 superinfection acquired heterosexually. The infected individual was in a high-risk cohort in Tanzania, was exposed to multiple subtypes, and was systematically evaluated every 3 months with a fluorescent multi-region genotyping assay. The subject was identified in the window period and was first infected with a complex ACD recombinant strain, became superinfected 6 to 9 months later with an AC recombinant, and was monitored for >2.5 years. The plasma viral load exceeded 400,000 copies/ml during the first 9 months of infection but resolved to the set point of 67,000 copies/ml by 3 months after superinfection; the CD4 cell count was 377 cells/mul at 30 months. Viral diversity was evaluated with techniques designed to fully sample the quasi-species, permitting direct observation of the evolution, temporal fluctuation, and intercompartment dynamics of the initial and superinfecting strains and recombinants derived from them. Within 3 months of superinfection, seven different molecular forms were detected in gag and six were detected in env. The proportions of forms fluctuated widely over time in plasma and peripheral blood mononuclear cells, illustrating how challenging the detection of dually infected individuals can be. Strain-specific nested PCR confirmed that the superinfecting strain was not present until the 9 month follow-up. This study further defines the parameters and dynamics of superinfection and will foster appropriate studies and approaches to gain a more complete understanding of risk factors for superinfection and its impact on clinical progression, epidemiology, and vaccine design. 相似文献
5.
Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3 下载免费PDF全文
Meloni ST Kim B Sankalé JL Hamel DJ Tovanabutra S Mboup S McCutchan FE Kanki PJ 《Journal of virology》2004,78(22):12438-12445
Phylogenetic analyses demonstrate significant diversity in worldwide circulating strains of human immunodeficiency virus type 1 (HIV-1). Detailed studies have revealed a complex pattern of intersubtype recombinations, as well as evidence of sub-subtypes circulating in various populations. In this study, we characterized an HIV-1 strain that had previously been identified as a distinct subcluster within the subtype A radiation based on partial sequence data. These viruses were of particular interest given that we recently found that their prevalence was significantly higher in dually infected individuals compared to women who were singly infected with HIV-1. Five viruses isolated from commercial sex workers in Dakar, Senegal, were full-length PCR amplified and sequenced. Phylogenetic analyses indicated that, whereas three of these viruses were closely related and clustered overall within the HIV-1 subtype A radiation, they were distinct from previously characterized sub-subtype A1 and A2 viruses. The clustering pattern was maintained in the individual gag, pol, and env regions of the genome. Distance calculations between these viruses, which we termed A3, and other reference sub-subtype A1 and A2 viruses fell in the range of distances between previously characterized sub-subtype groups. In addition, we found evidence of two A3-containing recombinants in our cohort. These recombinants are mosaics composed of sequence from both sub-subtype A3 and CRF02_AG, the major circulating recombinant form in this West African population. Based on phylogenetic analyses, we propose that the group of viruses found in the Dakar sex worker cohort, previously referred to as HIV-1 A subcluster 2, be referred to as HIV-1 sub-subtype A3. 相似文献
6.
Kristina K. Peachman Nicos Karasavvas Agnes-Laurence Chenine Robert McLinden Supachai Rerks-Ngarm Kaewkungwal Jaranit Sorachai Nitayaphan Punnee Pitisuttithum Sodsai Tovanabutra Susan Zolla-Pazner Nelson L. Michael Jerome H. Kim Carl R. Alving Mangala Rao 《PloS one》2015,10(12)
Background
The gut mucosal homing integrin receptor α4β7 present on activated CD4+ T cells interacts with the HIV-1 gp120 second variable loop (V2). Case control analysis of the RV144 phase III vaccine trial demonstrated that plasma IgG binding antibodies specific to scaffolded proteins expressing the first and second variable regions (V1V2) of HIV envelope protein gp120 containing the α4β7 binding motif correlated inversely with risk of infection. Subsequently antibodies to the V3 region were also shown to correlate with protection. The integrin receptor α4β7 was shown to interact with the LDI/V motif on V2 loop but recent studies suggest that additional regions of V2 loop could interact with the α4β7. Thus, there may be several regions on the V2 and possibly V3 loops that may be involved in this binding. Using a cell line, that constitutively expressed α4β7 receptors but lacked CD4, we examined the contribution of V2 and V3 loops and the ability of V2 peptide-, V2 integrin-, V3-specific monoclonal antibodies (mAbs), and purified IgG from RV144 vaccinees to block the V2/V3-α4β7 interaction.Results
We demonstrate that α4β7 on RPMI8866 cells bound specifically to its natural ligand mucosal addressin cell adhesion molecule-1 (MAdCAM-1) as well as to cyclic-V2 and cyclic-V3 peptides. This binding was inhibited by anti-α4β7-specific monoclonal antibody (mAb) ACT-1, mAbs specific to either V2 or V3 loops, and by purified primary virions or infectious molecular clones expressing envelopes from acute or chronic subtypes A, C, and CRF01_AE viruses. Plasma from HIV-1 infected Thai individuals as well as purified IgG from uninfected RV144 vaccinees inhibited (0–50%) the binding of V2 and V3 peptides to α4β7.Conclusion
Our results indicate that in addition to the tripeptide LDI/V motif, other regions of the V2 and V3 loops of gp120 were involved in binding to α4β7 receptors and this interaction was blocked by anti-V2 peptide, anti-V2 integrin, and anti-V3 antibodies. The ability of purified IgG from some of the uninfected RV144 vaccinees to inhibit α4β7 raises the hypothesis that anti-V2 and anti-V3 antibodies may play a role in blocking the gp120-α4β7 interaction after vaccination and thus prevent HIV-1 acquisition. 相似文献7.
Rolland M Tovanabutra S deCamp AC Frahm N Gilbert PB Sanders-Buell E Heath L Magaret CA Bose M Bradfield A O'Sullivan A Crossler J Jones T Nau M Wong K Zhao H Raugi DN Sorensen S Stoddard JN Maust BS Deng W Hural J Dubey S Michael NL Shiver J Corey L Li F Self SG Kim J Buchbinder S Casimiro DR Robertson MN Duerr A McElrath MJ McCutchan FE Mullins JI 《Nature medicine》2011,17(3):366-371
We analyzed HIV-1 genome sequences from 68 newly infected volunteers in the STEP HIV-1 vaccine trial. To determine whether the vaccine exerted selective T cell pressure on breakthrough viruses, we identified potential T cell epitopes in the founder sequences and compared them to epitopes in the vaccine. We found greater distances to the vaccine sequence for sequences from vaccine recipients than from placebo recipients. The most significant signature site distinguishing vaccine from placebo recipients was Gag amino acid 84, a site encompassed by several epitopes contained in the vaccine and restricted by human leukocyte antigen (HLA) alleles common in the study cohort. Moreover, the extended divergence was confined to the vaccine components of the virus (HIV-1 Gag, Pol and Nef) and not found in other HIV-1 proteins. These results represent what is to our knowledge the first evidence of selective pressure from vaccine-induced T cell responses on HIV-1 infection in humans. 相似文献
8.
Peter Hraber Bette T. Korber Alan S. Lapedes Robert T. Bailer Michael S. Seaman Hongmei Gao Kelli M. Greene Francine McCutchan Carolyn Williamson Jerome H. Kim Sodsai Tovanabutra Beatrice H. Hahn Ronald Swanstrom Michael M. Thomson Feng Gao Linda Harris Elena Giorgi Nicholas Hengartner Tanmoy Bhattacharya John R. Mascola David C. Montefiori 《Journal of virology》2014,88(21):12623-12643
9.
10.
Gustavo H. Kijak Sodsai Tovanabutra Supachai Rerks-Ngarm Sorachai Nitayaphan Chirapa Eamsila Prayura Kunasol Chirasak Khamboonruang Prasert Thongcharoen Chawetsan Namwat Nakorn Premsri Michael Benenson Patricia Morgan Meera Bose Eric Sanders-Buell Robert Paris Merlin L. Robb Deborah L. Birx Mark S. De Souza Francine E. McCutchan Nelson L. Michael Jerome H. Kim 《Journal of virology》2013,87(23):13084